

Convalescent Plasma Trials Update

Total number of patients randomised:

501



50% of all patients randomised will receive convalescent plasma, and each patient will receive 2 units.

For clinical trials, an Independent **Data Monitoring Committee (DMC)** should be established to review the safety of the drug or product being investigated. The RECOVERY trial's DMC conducted a safety review (24th August) of all patients randomised to the trial (including 200 patients randomised to the convalescent plasma arm).

Which was the latest hospital to open the REMAP-CAP trial?



Queen Elizabeth Hospital, Gateshead

Which was the latest hospital to open the RECOVERY trial?



Craigavon Area Hospital



The DMC found no concerns regarding safety and agreed that recruitment into the trial should continue.



- Start Date: **26/05/2020**
- Number of hospitals open: **162**
- Number of patients randomised: **392**
- Further information about the trial:
www.recoverytrial.net

SUMMARY OF TRIAL INCLUSION CRITERIA

- Hospitalised (any age)
- SARS-CoV-2 infection (clinically suspected or laboratory confirmed)
- No medical history that might put the patient at significant risk if he/she were to participate in the trial



- Start Date: **30/04/2020**
- Number of hospitals open: **113**
- Number of patients randomised: **109**
- Further information about the trial:
www.remapcap.org

SUMMARY OF TRIAL INCLUSION CRITERIA

- Adults admitted to an Intensive Care Unit
- SARS-CoV-2 infection (laboratory confirmed)
- No medical history that might put the patient at significant risk if he/she were to participate in the trial